Percutaneous coronary intervention with transcatheter aortic valve replacement makes no difference! None? Really?
Peter C BlockArnav KumarPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Unless a patient who needs transcatheter aortic valve replacement (TAVR) presents with an acute coronary syndrome, "routine" percutaneous coronary intervention of coronary stenoses does not improve outcomes, even out to 5 years. Randomized clinical trials are needed to sort out the best strategies to treat the complex interaction of coronary disease and aortic stenosis, though they are unlikely to be performed. Without such evidence, patients undergoing TAVR need the judgment of a Heart Team to help strategize whether revascularization for CAD should be performed.
Keyphrases
- percutaneous coronary intervention
- transcatheter aortic valve replacement
- aortic stenosis
- acute coronary syndrome
- coronary artery disease
- st segment elevation myocardial infarction
- aortic valve
- aortic valve replacement
- antiplatelet therapy
- coronary artery bypass grafting
- transcatheter aortic valve implantation
- acute myocardial infarction
- st elevation myocardial infarction
- patients undergoing
- atrial fibrillation
- coronary artery bypass
- heart failure
- palliative care
- case report
- coronary artery
- clinical practice
- type diabetes
- clinical trial
- ejection fraction
- quality improvement